Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests investors …

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath …